A Study of QLS5132 in Platinum-Resistant Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
A Phase III, Multicenter, Randomized, Open-Label, Controlled Study of QLS5132 Versus Investigator's Choice of Chemotherapy in Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
The goal of this interventional study is to compare the effectiveness and safety of QLS5132 monotherapy with investigator's choice of chemotherapy in participants with platinum-resistant recurrent epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.
調査の概要
状態
研究の種類
入学 (推定)
段階
- フェーズ 3
連絡先と場所
研究連絡先
- 名前：Tao Zhu, Master
- 電話番号：13858065156
- メール：zhutao@zjcc.org.cn
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Female participants aged ≥ 18 years.
- Histologically confirmed epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.
- Platinum-resistant recurrent disease, defined as disease progression within 6 months (≤183 days) after the last platinum-based chemotherapy.
- At least one measurable lesion per RECIST v1.1.
- ECOG performance status of 0 or 1.
- Expected survival ≥ 12 weeks.
- Adequate organ and bone marrow function.
- Negative pregnancy test for women of childbearing potential, and agreement to use effective contraception.
Exclusion Criteria:
- Prior treatment with CLDN6-targeting therapy or topoisomerase I inhibitors (e.g., topotecan, trastuzumab deruxtecan).
- Active or untreated central nervous system (CNS) metastases or carcinomatous meningitis. (Patients with stable, treated CNS metastases may be eligible).
- Clinically significant cardiovascular disease, including QTc ≥ 470 ms, LVEF < 50%, or uncontrolled hypertension.
- Active infections (e.g., HBV, HCV, HIV, tuberculosis, syphilis).
- Active or history of autoimmune diseases requiring systemic treatment.
- Severe liver disease (Child-Pugh B or C), uncontrolled diabetes, or other severe medical conditions that may interfere with the study.
研究計画
研究はどのように設計されていますか？
デザインの詳細
- 主な目的：処理
- 割り当て：ランダム化
- 介入モデル：並列代入
- マスキング：なし（オープンラベル）
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的：QLS5132 Monotherapy
|
Intravenous infusion, Q3W (Day 1 of each 21-day cycle) |
|
アクティブコンパレータ：QLS5132 Investigator's Choice of Chemotherapy
|
Intravenous infusion, Q4W (Day 1 of each 28-day cycle) Intravenous infusion, Q4W (Days 1, 8, 15, and 22 of each 28-day cycle) Intravenous infusion, Q4W (Days 1, 8, and 15 of each 28-day cycle) |
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Progression-Free Survival (PFS) Assessed by BICR
時間枠：From randomization to the first documented disease progression as assessed by blinded independent central review (BICR) using RECIST v1.1, or death from any cause, whichever occurs first, assessed up to approximately 3 years.
|
Time from randomization to the first documented disease progression as assessed by blinded independent central review (BICR) using RECIST v1.1, or death from any cause, whichever occurs first. |
From randomization to the first documented disease progression as assessed by blinded independent central review (BICR) using RECIST v1.1, or death from any cause, whichever occurs first, assessed up to approximately 3 years.
|
|
Overall Survival (OS)
時間枠：From randomization until death from any cause, assessed up to approximately 3 years.
|
Time from randomization to death from any cause. |
From randomization until death from any cause, assessed up to approximately 3 years.
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
- QLS5132-301
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。